Literature DB >> 8337988

Asthma and vasculitis. Response to intravenous immunoglobulins.

A Armentia1, A Fernández, P Sánchez, R de la Fuente, E Sanchís, J Méndez, I Parra, M Puyo.   

Abstract

A 17-year old woman suffered progressively worse asthma attacks with hypereosinophilia, patchy lung infiltrates, and acute ischemic lesions of the fingers and purpuric lesions suggesting vasculitis. She developed hypoxemic respiratory failure despite treatment with high-dose corticosteroids. Intravenous cyclophosphamide was introduced with good clinical response, but had to be discontinued because of intolerance. Intravenous immunoglobulins were given in monthly doses for 10 months while the corticosteroid dose was tapered off. This treatment was associated with rapid clinical and biochemical improvement without adverse effects. We conclude that intravenous immunoglobulins is a useful complementary treatment for patients with severe asthma associated with pulmonary vasculitis refractory to corticosteroid therapy alone.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8337988

Source DB:  PubMed          Journal:  Allergol Immunopathol (Madr)        ISSN: 0301-0546            Impact factor:   1.667


  4 in total

1.  Churg-Strauss syndrome.

Authors:  P Ramnarayan; S Sowmya; N Biswal; P Nalini; C Ratnakar
Journal:  Indian J Pediatr       Date:  1998 May-Jun       Impact factor: 1.967

2.  Long term effectiveness of intravenous immunoglobulin in Churg-Strauss syndrome.

Authors:  M G Danieli; M Cappelli; G Malcangi; F Logullo; A Salvi; G Danieli
Journal:  Ann Rheum Dis       Date:  2004-12       Impact factor: 19.103

Review 3.  Intravenous immunoglobulin therapy in vasculitis: speculation or evidence?

Authors:  Peer Malte Aries; Bernhard Hellmich; Wolfgang Ludwig Gross
Journal:  Clin Rev Allergy Immunol       Date:  2005-12       Impact factor: 8.667

4.  Marked improvement of Churg-Strauss vasculitis with intravenous gamma globulins during pregnancy.

Authors:  Arnaud Hot; Laurent Perard; Brigitte Coppere; Marie Simon; Françoise Bouhour; Jacques Ninet
Journal:  Clin Rheumatol       Date:  2007-05-08       Impact factor: 2.980

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.